Potent plasmablast-derived antibodies elicited by the National Institutes of Health dengue vaccine

Journal of Virology

Volumn 91, Issue 22, 2017, Pages

  Magnani, Diogo M ^a   Silveira, Cassia G T ^b   Ricciardi, Michael J ^a   Gonzalez Nieto, Lucas ^a   Pedreño Lopez, Núria ^a   Bailey, Varian K ^a   Gutman, Martin J ^a   Maxwell, Helen S ^a   Domingues, Aline ^a   Costa, Priscilla R ^b   Ferrari, Lilian ^b   Goulart, Raphaella ^b   Martins, Mauricio A ^a   Martinez Navio, José M ^a   Fuchs, Sebastian P ^a   Kalil, Jorge ^b,c   Timenetsky, Maria do Carmo ^d   Wrammert, Jens ^e   Whitehead, Stephen S ^f   Burton, Dennis R ^g,h   Desrosiers, Ronald C ^a   Kallas, Esper G ^b   Watkins, David I ^a   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

^d INSTITUTO ADOLFO LUTZ   (Brazil)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

^h MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

B cell; Butantan DV; Dengue; Monoclonal antibodies; Plasmablast; TV003; Vaccines

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; P3D05 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ARTICLE; CELL EXPANSION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DENGUE VIRUS 3; HUMAN; HUMAN CELL; NATIONAL HEALTH ORGANIZATION; PLASMABLAST; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; VACCINATION; VIRUS NEUTRALIZATION; ADULT; CLINICAL TRIAL; FEMALE; HEK293 CELL LINE; IMMUNOLOGY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PLASMA CELL; UNITED STATES;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HEK293 CELLS; HUMANS; MALE; NATIONAL INSTITUTES OF HEALTH (U.S.); PLASMA CELLS; UNITED STATES;

EID: 85032272521     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00867-17     Document Type: Article

References (48)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. https://doi.org/ 10.1038/nature12060.
2. Guy B, Briand O, Lang J, Saville M, Jackson N. 2015. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine 33:7100-7111. https://doi.org/10.1016/j.vaccine.2015.09.108.
3. Whitehead SS. 2016. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine? Expert Rev Vaccines 15:509-517. https://doi.org/10.1586/14760584.2016.1115727.
4. Osorio JE, Wallace D, Stinchcomb DT. 2016. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines 15:497-508. https://doi.org/10.1586/ 14760584.2016.1128328.
5. Halstead SB. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421-467. https://doi.org/10.1016/S0065-3527(03)60011-4.
6. Halstead SB, Nimmannitya S, Cohen SN. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42: 311-328.
7. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. https://doi.org/10.1016/ S0140-6736(12)61428-7.
8. Halstead SB. 2013. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 31:4501-4507. https://doi.org/ 10.1016/j.vaccine.2013.06.079.
9. Halstead SB. 2012. Dengue vaccine development: a 75% solution? Lancet 380:1535-1536. https://doi.org/10.1016/S0140-6736(12)61510-4.
10. Swaminathan S, Khanna N, Herring B, Mahalingam S. 2013. Dengue vaccine efficacy trial: does interference cause failure? Lancet Infect Dis 13:191-192. https://doi.org/10.1016/S1473-3099(13)70028-8.
11. Wilder-Smith A, Massad E. 2016. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Rev Vaccines 15:437-441. https://doi.org/10.1586/14760584.2016.1143366.
12. Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP. 2016. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med 8:330ra336. https://doi.org/10.1126/scitranslmed.aaf1517.
13. Acosta EG, Bartenschlager R. 2016. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Expert Rev Vaccines 15:467-482. https://doi.org/10.1586/ 14760584.2016.1121814.
14. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329:112-124. https://doi.org/10.1016/j.jim.2007.09.017.
15. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. 2010. Crossreacting antibodies enhance dengue virus infection in humans. Science 328:745-748. https://doi.org/10.1126/science.1185181.
16. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283. https://doi.org/ 10.1016/j.chom.2010.08.007.
17. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. 2016. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci U S A 113:728-733. https://doi.org/10.1073/pnas.1522136113.
18. Tsai W-Y, Lai C-Y, Wu Y-C, Lin H-E, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang W-K. 2013. Highavidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol 87: 12562-12575. https://doi.org/10.1128/JVI.00871-13.
19. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE, Jr. 2012. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86:2665-2675. https://doi.org/10.1128/JVI.06335-11.
20. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE, Jr. 2013. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique crossreactive epitope on the bc loop of domain II of the envelope protein. mBio 4:e00873-13. https://doi.org/10.1128/mBio.00873-13.
21. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170-177. https://doi.org/10.1038/ni.3058.
22. Priyamvada L, Cho A, Onlamoon N, Zheng NY, Huang M, Kovalenkov Y, Chokephaibulkit K, Angkasekwinai N, Pattanapanyasat K, Ahmed R, Wilson PC, Wrammert J. 2016. B cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Virol 90:5574-5585. https://doi.org/10.1128/JVI.03203-15.
23. Srikiatkhachorn A, Yoon IK. 2016. Immune correlates for dengue vaccine development. Expert Rev Vaccines 15:455-465. https://doi.org/10.1586/ 14760584.2016.1116949.
24. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE, Jr. 2013. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 207:1898-1908. https://doi.org/10.1093/infdis/jit119.
25. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. 2013. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 207:957-965. https://doi.org/ 10.1093/infdis/jis936.
26. Kwissa M, Nakaya HI, Onlamoon N, Wrammert J, Villinger F, Perng GC, Yoksan S, Pattanapanyasat K, Chokephaibulkit K, Ahmed R, Pulendran B. 2014. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe 16:115-127. https://doi.org/10.1016/j.chom.2014.06.001.
27. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, Kwissa M, Pulendran B, Wilson PC, Wittawatmongkol O, Yoksan S, Angkasekwinai N, Pattanapanyasat K, Chokephaibulkit K, Ahmed R. 2012. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol 86:2911-2918. https://doi.org/ 10.1128/JVI.06075-11.
28. de Alwis R, de Silva AM. 2014. Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique. Methods Mol Biol 1138:27-39. https://doi.org/10.1007/978-1-4939-0348-1_3.
29. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM. 2015. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 6:6341. https://doi.org/10.1038/ ncomms7341.
30. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109:7439-7444. https://doi.org/10.1073/pnas.1200566109.
31. Halstead SB, Russell PK. 2016. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 34:1643-1647. https:// doi.org/10.1016/j.vaccine.2016.02.004.
32. Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, Ong SH, Warter L, Leo YS, Wang CI, Fink K. 2012. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J Immunol 189:5877-5885. https://doi.org/10.4049/jimmunol.1201688.
33. Garcia-Bates TM, Cordeiro MT, Nascimento EJ, Smith AP, Soares de Melo KM, McBurney SP, Evans JD, Marques ET, Jr, Barratt-Boyes SM. 2013. Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients. J Immunol 190:80-87. https://doi.org/10.4049/jimmunol.1103350.
34. Nishiura H, Halstead SB. 2007. Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J Infect Dis 195: 1007-1013. https://doi.org/10.1086/511825.
35. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 109:9047-9052. https://doi.org/10.1073/pnas.1118979109.
36. Halliley JL, Kyu S, Kobie JJ, Walsh EE, Falsey AR, Randall TD, Treanor J, Feng C, Sanz I, Lee FE. 2010. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine 28:3582-3587. https://doi.org/10.1016/j.vaccine.2010.02.088.
37. Godoy-Lozano EE, Tellez-Sosa J, Sanchez-Gonzalez G, Samano-Sanchez H, Aguilar-Salgado A, Salinas-Rodriguez A, Cortina-Ceballos B, Vivanco-Cid H, Hernandez-Flores K, Pfaff JM, Kahle KM, Doranz BJ, Gomez-Barreto RE, Valdovinos-Torres H, Lopez-Martinez I, Rodriguez MH, Martinez-Barnetche J. 2016. Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal centerindependent B cell response. Genome Med 8:23. https://doi.org/10.1186/s13073-016-0276-1.
38. Avnir Y, Tallarico AS, Zhu Q, Bennett AS, Connelly G, Sheehan J, Sui J, Fahmy A, Huang CY, Cadwell G, Bankston LA, McGuire AT, Stamatatos L, Wagner G, Liddington RC, Marasco WA. 2014. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog 10:e1004103. https:// doi.org/10.1371/journal.ppat.1004103.
39. Chan CH, Hadlock KG, Foung SK, Levy S. 2001. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97:1023-1026.
40. Victora GD, Nussenzweig MC. 2012. Germinal centers. Annu Rev Immunol 30:429-457. https://doi.org/10.1146/annurev-immunol-020711-075032.
41. Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, Yang HO, Tan WL, Liu R, Yu M, Ge BX, Zhu QY, Qin ED, Guo YJ, Qin CF. 2011. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One 6:e16059. https://doi.org/ 10.1371/journal.pone.0016059.
42. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e1188. https:// doi.org/10.1371/journal.pntd.0001188.
43. Friberg H, Jaiswal S, West K, O'Ketch M, Rothman AL, Mathew A. 2012. Analysis of human monoclonal antibodies generated by dengue virusspecific memory B cells. Viral Immunol 25:348-359. https://doi.org/10.1089/vim.2012.0010.
44. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortes M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, CYD-TDV Dengue Vaccine Working Group. 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195-1206.
45. Fink K. 2012. Origin and function of circulating plasmablasts during acute viral infections. Front Immunol 3:78. https://doi.org/10.3389/ fimmu.2012.00078.
46. Brochet X, Lefranc MP, Giudicelli V. 2008. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36:W503-W508. https://doi.org/10.1093/nar/gkn316.
47. Kraus AA, Messer W, Haymore LB, de Silva AM. 2007. Comparison of plaque-and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45:3777-3780. https://doi.org/10.1128/ JCM.00827-07.
48. Brien JD, Lazear HM, Diamond MS. 2013. Propagation, quantification, detection, and storage of West Nile virus. Curr Protoc Microbiol 31: 15D.3.1-15D.3.18.